HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that detailed new peer-reviewed data from the most recently completed clinical studies of NX-1207, the Company’s drug in development for benign prostatic hyperplasia (BPH) will be presented at the Northeastern Section of the American Urological Association Meeting on September 18 in Santa Ana Pueblo, New Mexico. The Nymox investigational drug has entered Phase 3 development.
